Country Risk: My 2024 Data Update
After the 2008 market crisis, I resolved that I would be far more organized in my assessments and updating of equity risk premiums, in the United States and abroad, as I looked at the damage that can be inflicted on intrinsic value by significant shifts in risk premiums, i.e., my definition of a crisis. That precipitated my practice of estimating implied equity risk premiums for the S&P 500, at the start of every month, and following up of using those estimated premiums when valuing companies during that month. The 2008 crisis also gave rise to two risk premium papers that I have updated each year: the first looks at equity risk premiums, what they measure, how they vary across time and how best to estimate them, with the last update in March 2024. The second focuses on country risk and how it varies across geographies, with the focus again on determinants, measures and estimation, which I update mid-year each year. This post reflects my most recent update from July 2024 of country risk, and while you can read the entire paper here, I thought I would give you a mildly abridged version in this post.
Country Risk: Determinants
At the risk of stating the obvious, investing and operating in some countries is much riskier than investing and operating in others, with variations in risk on multiple dimensions. In the section below, I highlight the differences on four major dimensions – political structure, exposure to war/violence, extent of corruption and protections for legal and property rights, with the focus firmly on the economic risks rather than on social consequences.
a. Political Structure
Would you rather invest/operate in a democracy than in an autocracy? From a business risk perspective, I would argue that there is a trade off, sometimes making the former more risky than the latter, and sometimes less so. The nature of a democracy is that a government will be less able to promise or deliver long term predictable/stable tax and regulatory law, since losing an election can cause shifts in policy. Consequently, operating and investing in a democratic country will generally come with more risk on a continuous basis, with the risk increasing with partisanship in the country. Autocratic governments are in a better position to promise and deliver stable and predictable business environments, with two caveats. The first is that when change comes in autocracies, it will be both unexpected and large, with wrenching and discontinuous shifts in economic policy. The second is that the absence of checks and balance (legal, legislative, public opinion) will also mean that policy changes can be capricious, often driven by factors that have little to do with business or public welfare.
Any attempt to measure political freedom comes with qualifiers, since the biases of the measuring service on what freedoms to elevate and which ones to ignore will play a role, but in the figure below, I report the Economist’s Democracy Index, which is based upon five measures – electoral process and pluralism, government functioning, political participation, democratic social culture and civil liberties:
Democracy Index in 2023: Source: The Economist |
Global Peace Index 2024: Source: Institute for Economics & Peace |
Corruption Index 2023: Source: Transparency International |
Property Rights Index 2023: Source: The Property Rights Alliance |
Source: Maplecroft |
National security is the reason that some governments use to justify public ownership of key resources. For instance, in 2022, Mexico created a state-owned company, Litio Para Mexico, to have a monopoly on lithium mining in the country, and announced a plan to renegotiate previously granted concessions to private companies to extract the resource.
Proportion of revenues from commodities- 2019-2021; Source: UNCTAD |
Climate Risk Index (CRI) in 2021: ResourceWatch |
Moody’s Sovereign Ratings in July 2024; Source: Moody’s |
Sovereign CDS Spreads on June 30, 2024: Source: Bloomberg |
Country risk scores in July 2024: Political Risk Services |
Download spreadsheet |
Country Risk in Decision Making
At this point, your reaction to this discussion might be “so what?”, since you may see little use for these concepts in practice, either as a business or as an investor. In this section, I will argue that understanding equity risk premiums, and how they vary across geographies, can be critical in both business and personal investing.
Country Risk in Business
Most corporate finance classes and textbooks leave students with the proposition that the right hurdle rate to use in assessing business investments is the cost of capital, but create a host of confusion about what exactly that cost of capital measures. Contrary to popular wisdom, the cost of capital to use when assessing investment quality has little to do with the cost of raising financing for a company and more to do with coming up with an opportunity cost, i.e., a rate of return that the company can generate on investments of equivalent risk. Thus defined, you can see that the cost of capital that a company uses for an investment should reflect both the business risk as well as where in the world that investment is located. For a multinational consumer product company, such as Coca Cola, the cost of capital used to assess the quality of a Brazilian beverage project should be very different from the cost of capital estimated for a German beverage project, even if both are estimated in US dollars. The picture below captures the ingredients that go into a hurdle rate:
Thus, in computing costs of equity and capital for its Brazil and German projects, Coca Cola will be drawing on the equity risk premiums for Brazil (7.87%) and Germany (4.11%), leading to higher hurdle rates for the former.
The implications for multi-business, multi-national companies is that there is no one corporate cost of capital that can be used in assessing investments, since it will vary both across businesses and across geographies. A company in five businesses and ten geographies, with have fifty different costs of capital, and while you complaint may that this is too complicated, ignoring it and using one corporate cost of capital will lead you to cross subsidization, with the safest businesses and geographies subsidizing the riskiest.
Country Risk in Investing
As investors, we invest in companies, not projects, with those companies often having exposures in many countries. While it is possible to value a company in pieces, by valuing each its operations in each country, the absence of information at the country level often leads us to valuing the entire company, and when doing so, the risk exposure for that company comes from where it operates, not where it does business. Thus, when computing its cost of equity, you should look not only at its businesss risk, but what parts of the world it operates in:
In intrinsic valuation, this will imply that a company with more of its operations in risky countries will be worth less than a company with equivalent earnings, growth and cash flows with operations in safer countries. Thus, rather than look at where a company is incorporated and traded, we should be looking at where it operates, both in terms of production and revenues; Nvidia is a company incorporated and traded in the United States, but as a chip designed almost entirely dependent on TSMC for its chip manufacture, it is exposed to China risk.
It is true that most investors price companies, rather than value them, and use pricing metrics (PE ratios, EV to EBITDA) to judge cheap or expensive. If our assessment of country risk hold, we should expect to see variations in these pricing metrics across geographies. We computed EV to EBITDA multiples, based upon aggregate enterprise value and EBITDA, by country, in July 2024, and the results are captured in the figure below:
Source: Raw data from S&P Capital IQ |
The results are mixed. While some of the riskiest parts of the world trade at low multiples of EBITDA, a significant part of Europe also does, including France and Norway. In fact, India trades at the highest multiple of EBITDA of any country in the world, representing how growth expectations can trump risk concerns.
Currency Effects
You may find it odd that I have spent so much of this post talking about country risk, without bringing up currencies, but that was not an oversight. It is true that riskier countries often have more volatile currencies that depreciate over time, but this more a symptom of country risk, than a cause. As I will argue in this section, currency choice affects your growth, cash flow and discount rate estimates, but ultimately should have no effect on intrinsic value.
If you value a company in US dollars, rather than Indian rupees, should the numbers in your valuation be different? Of course, but the reason for the differences lies in the fact that different currencies bring different inflation expectations with them, and the key is to stay consistent:
As we noted in the last section, the place that currency enters your valuation is in the riskfree rate, and if my assertion about expected inflation is right, variations in riskfree rates can be attributed entirely to difference in expected inflation. At the start of July 2024, for instance, I estimated the riskfree rates in every currency, using the US treasury bond rate as my dollar riskfree rate, and the differential inflation between the currency in question and the US dollar:
My estimates are in the appendix to this post. In the same vein, inflation also enters into expected exchange rate calculations:
This is, of course, the purchasing power parity theorem, and while currencies can deviate from this in the short term, it remains the best way to ensure that your currency views do not hijack your valuation.
- Equity risk premiums, by country – July 2024 (also includes ratings, PRS scores and sovereign CDS)
- Riskfree rates in currencies, based upon differential inflation – July 2024
External Data Links
Source: https://aswathdamodaran.blogspot.com/2024/07/country-risk-my-2024-data-update.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.